Overview

Efficacy and Safety of An'Ningpai Expectorant in Non-CF Bronchiectasis

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study was to assess whether the long-term use of oral An'Ningpai Enteric Soft Capsuleson (300 mg, three times daily, 12 months) might reduce the incidence of exacerbations and improve the quality of life in patients with Non-CF bronchiectasis.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Treatments:
Expectorants
Criteria
Inclusion Criteria:

1) subjects older than 18 ; 2)a diagnosis of bronchiectasis was according to the 2010
British Thoracic Society guidelines; 3) with hypersecretion :high viscous sputum symptoms
(sputum traits score 2-3 points) ;4) patients had least two exacerbations in the past year
and were in a state for at least 4 weeks prior to randomization

Exclusion Criteria:

1) cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary
aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis,
etc.); 2)primary diagnosis of COPD or asthma; 3)a history of severe cardiovascular disease;
4)comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or
intestinal malabsorption; 5)a known allergy to Eucalyptol , Limonene and Pinene Enteric
Soft Capsules; 6)pregnancy or lactation (for women);7)a history of prior macrolide use of
more than 1 week; 8)and poor compliance